David R Boulware

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4652863/publications.pdf

Version: 2024-02-01

298 papers 14,335 citations

28274 55 h-index 27406 106 g-index

314 all docs

314 docs citations

314 times ranked 13509 citing authors

#	Article	IF	CITATIONS
1	Technical procedures and REDCap tools for internet-based clinical trials. Contemporary Clinical Trials, 2022, 114, 106660.	1.8	3
2	Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries. Medical Mycology, 2022, 60, .	0.7	1
3	Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms. Open Forum Infectious Diseases, 2022, 9, ofac066.	0.9	17
4	"There are many fevers― Communities' perception and management of Febrile illness and its relationship with human animal interactions in South-Western Uganda. PLoS Neglected Tropical Diseases, 2022, 16, e0010125.	3.0	0
5	Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. New England Journal of Medicine, 2022, 386, 1109-1120.	27.0	119
6	Effect of Early Treatment with Ivermectin among Patients with Covid-19. New England Journal of Medicine, 2022, 386, 1721-1731.	27.0	142
7	Integrating central nervous system metagenomics and host response for diagnosis of tuberculosis meningitis and its mimics. Nature Communications, 2022, 13, 1675.	12.8	38
8	Can COVID-19 changes reduce stigma in African HIV clinics?. Lancet HIV,the, 2022, , .	4.7	1
9	Fluvoxamine for the treatment of COVID-19. The Lancet Global Health, 2022, 10, e329.	6.3	3
10	Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases. Open Forum Infectious Diseases, 2022, 9, .	0.9	25
11	Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization. JAMA Network Open, 2022, 5, e226269.	5.9	48
12	Determinants of cryptococcal antigen (CrAg) screening uptake in Kampala, Uganda: An assessment of health center characteristics. Medical Mycology, 2022, 60, .	0.7	1
13	Hydroxychloroquine for COVID19: The curtains close on a comedy of errors. The Lancet Regional Health Americas, 2022, 11, 100268.	2.6	14
14	Association of Hyponatremia on Mortality in Cryptococcal Meningitis: A Prospective Cohort. Open Forum Infectious Diseases, 2022, 9, .	0.9	5
15	Cerebrospinal fluid AFB smear in adults with tuberculous meningitis: A systematic review and diagnostic test accuracy meta-analysis. Tuberculosis, 2022, 135, 102230.	1.9	8
16	Early empiric anti- <i>Mycobacterium tuberculosis</i> therapy for sepsis in sub-Saharan Africa: a protocol of a randomised clinical trial. BMJ Open, 2022, 12, e061953.	1.9	1
17	Cerebrospinal Fluid Bacillary Load by Xpert MTB/RIF Ultra Polymerase Chain Reaction Cycle Threshold Value Predicts 2-Week Mortality in Human Immunodeficiency Virus–Associated Tuberculous Meningitis. Clinical Infectious Diseases, 2021, 73, e3505-e3510.	5.8	9
18	Cerebrospinal Fluid Lactate as a Prognostic Marker of Disease Severity and Mortality in Cryptococcal Meningitis. Clinical Infectious Diseases, 2021, 73, e3077-e3082.	5.8	11

#	Article	IF	CITATIONS
19	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. Clinical Infectious Diseases, 2021, 72, e835-e843.	5.8	103
20	Diagnostic accuracy of Xpert MTB/RIF for tuberculous meningitis: systematic review and metaâ€analysis. Tropical Medicine and International Health, 2021, 26, 122-132.	2.3	11
21	Ending deaths from HIV-related cryptococcal meningitis by 2030. Lancet Infectious Diseases, The, 2021, 21, 16-18.	9.1	18
22	Point-of-Care Lung Ultrasound for COVID-19: Findings and Prognostic Implications From 105 Consecutive Patients. Journal of Intensive Care Medicine, 2021, 36, 334-342.	2.8	26
23	Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19. Open Forum Infectious Diseases, 2021, 8, ofab050.	0.9	130
24	88462 Fluconazole distribution in CNS and gynecological tissues in HIV-related cryptococcal meningitis decedents. Journal of Clinical and Translational Science, 2021, 5, 96-96.	0.6	0
25	Sex-specific associations between cerebrospinal fluid inflammatory marker levels and cognitive function in antiretroviral treated people living with HIV in rural Uganda. Brain, Behavior, and Immunity, 2021, 93, 111-118.	4.1	9
26	High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clinical Infectious Diseases, 2021, 73, 876-884.	5.8	40
27	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. Annals of Internal Medicine, 2021, 174, 434-435.	3.9	12
28	Improved Influenza Diagnostics through Thermal Contrast Amplification. Diagnostics, 2021, 11, 462.	2.6	5
29	A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis. AIDS Research and Human Retroviruses, 2021, 37, 529-533.	1.1	1
30	High prevalence of Cryptococcal antigenemia using a finger-prick lateral flow assay in individuals with advanced HIV disease in Santar©m Municipality, Brazilian Amazon Basin. Medical Mycology, 2021, 59, 909-915.	0.7	3
31	Transcriptomic biomarker pathways associated with death in HIV-infected patients with cryptococcal meningitis. BMC Medical Genomics, 2021, 14, 108.	1.5	6
32	ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC50. Frontiers in Cellular and Infection Microbiology, 2021, 11, 695240.	3.9	5
33	Evaluation of the Diagnostic Performance of a Semiquantitative Cryptococcal Antigen Point-of-Care Assay among HIV-Infected Persons with Cryptococcal Meningitis. Journal of Clinical Microbiology, 2021, 59, e0086021.	3.9	10
34	Improvement in depressive symptoms after antiretroviral therapy initiation in people with HIV in Rakai, Uganda. Journal of NeuroVirology, 2021, 27, 519-530.	2.1	1
35	Establishing targets for advanced HIV disease: A call to action. Southern African Journal of HIV Medicine, 2021, 22, 1266.	0.9	9
36	Evaluation of the BioFire® FilmArray® Meningitis/Encephalitis panel in an adult and pediatric Ugandan population. Journal De Mycologie Medicale, 2021, 31, 101170.	1.5	15

#	Article	IF	Citations
37	Impact of biological sex on cryptococcal meningitis mortality in Uganda and South Africa. Medical Mycology, 2021, 59, 712-719.	0.7	3
38	Fujifilm SILVAMP TB LAM Assay on Cerebrospinal Fluid for the Detection of Tuberculous Meningitis in Adults With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, e3428-e3434.	5.8	20
39	Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic. Open Forum Infectious Diseases, 2021, 8, ofaa602.	0.9	9
40	Reply to Neves. Clinical Infectious Diseases, 2021, 73, e1772-e1774.	5.8	2
41	HIV-Associated Cryptococcal Meningitis Patients Treated with Amphotericin B Deoxycholate Plus Flucytosine under Routine Care Conditions in a Referral Center in São Paulo, Brazil. Mycopathologia, 2021, 186, 93-102.	3.1	4
42	Rates of refusal of clinical autopsies among HIV-positive decedents and an overview of autopsies in Uganda. Wellcome Open Research, 2021, 6, 302.	1.8	0
43	Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence. Drugs, 2021, 81, 2081-2089.	10.9	28
44	Change in Plasma Cryptococcal Antigen Titer Is Not Associated With Survival Among Human Immunodeficiency Virus–infected Persons Receiving Preemptive Therapy for Asymptomatic Cryptococcal Antigenemia. Clinical Infectious Diseases, 2020, 70, 353-355.	5.8	3
45	Cryptococcal Antigen Screening and Preemptive Treatment—How Can We Improve Survival?. Clinical Infectious Diseases, 2020, 70, 1691-1694.	5.8	12
46	Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management. Medical Mycology, 2020, 58, 282-292.	0.7	10
47	Cytomegalovirus Viremia Associated With Increased Mortality in Cryptococcal Meningitis in Sub-Saharan Africa. Clinical Infectious Diseases, 2020, 71, 525-531.	5.8	20
48	Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy–Experienced Ugandans With Virologic Failure. Clinical Infectious Diseases, 2020, 71, 1726-1731.	5.8	15
49	Burden of Depression in Outpatient HIV-Infected adults in Sub-Saharan Africa; Systematic Review and Meta-analysis. AIDS and Behavior, 2020, 24, 1752-1764.	2.7	46
50	Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials. Clinical Infectious Diseases, 2020, 71, e45-e49.	5.8	17
51	Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. Lancet Infectious Diseases, The, 2020, 20, 308-317.	9.1	80
52	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa500.	0.9	38
53	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. Annals of Internal Medicine, 2020, 173, 623-631.	3.9	444
54	Correlation between Blood and CSF Compartment Cytokines and Chemokines in Subjects with Cryptococcal Meningitis. Mediators of Inflammation, 2020, 2020, 1-6.	3.0	5

#	Article	IF	CITATIONS
55	Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	35
56	A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration. Aids, 2020, 34, 1425-1428.	2.2	9
57	Symptoms of COVID-19 Outpatients in the United States. Open Forum Infectious Diseases, 2020, 7, ofaa271.	0.9	38
58	Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda. BMC Infectious Diseases, 2020, 20, 572.	2.9	7
59	A Systematic Review of Treatment and Outcomes of Pregnant Women With COVID-19—A Call for Clinical Trials. Open Forum Infectious Diseases, 2020, 7, ofaa350.	0.9	25
60	Impact of community engagement and social support on the outcomes of HIV-related meningitis clinical trials in a resource-limited setting. Research Involvement and Engagement, 2020, 6, 49.	2.9	3
61	Treatment outcomes in adult tuberculous meningitis: a systematic review and meta-analysis. Open Forum Infectious Diseases, 2020, 7, ofaa257.	0.9	25
62	Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial. Medical Mycology, 2020, 58, 1037-1043.	0.7	12
63	Standardized Urine-Based Tuberculosis (TB) Screening With TB-Lipoarabinomannan and Xpert MTB/RIF Ultra in Ugandan Adults With Advanced Human Immunodeficiency Virus Disease and Suspected Meningitis. Open Forum Infectious Diseases, 2020, 7, ofaa100.	0.9	21
64	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. Canadian Journal of Anaesthesia, 2020, 67, 1201-1211.	1.6	19
65	Landmark clinical observations and immunopathogenesis pathways linked to HIV and <i>Cryptococcus</i> fatal central nervous system coâ€infection. Mycoses, 2020, 63, 840-853.	4.0	16
66	B Cell Compartmentalization in Blood and Cerebrospinal Fluid of HIV-Infected Ugandans with Cryptococcal Meningitis. Infection and Immunity, 2020, 88, .	2.2	9
67	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine, 2020, 383, 517-525.	27.0	1,081
68	Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27–30, 2018, Big Sky, Montana, a proposed global research agenda. Medical Mycology, 2020, 58, 569-578.	0.7	1
69	Xpert MTB/RIF Ultra for the Diagnosis of Tuberculous Meningitis: A Small Step Forward. Clinical Infectious Diseases, 2020, 71, 2002-2005.	5.8	27
70	Tuberculosis in HIV-Associated Cryptococcal Meningitis is Associated with an Increased Risk of Death. Journal of Clinical Medicine, 2020, 9, 781.	2.4	12
71	Efficacy of Cerebrospinal Fluid Beta- <scp>d</scp> -Glucan Diagnostic Testing for Fungal Meningitis: a Systematic Review. Journal of Clinical Microbiology, 2020, 58, .	3.9	19
72	Should we perform the serum cryptococcal antigen test in people living with HIV hospitalized due to a community-acquired pneumonia episode?. International Journal of STD and AIDS, 2020, 31, 345-350.	1.1	0

#	Article	IF	Citations
73	Finding the Dose for Hydroxychloroquine Prophylaxis for COVIDâ€19: The Desperate Search for Effectiveness. Clinical Pharmacology and Therapeutics, 2020, 108, 766-769.	4.7	46
74	Evaluation of Serum Cryptococcal Antigen Testing Using Two Novel Semiquantitative Lateral Flow Assays in Persons with Cryptococcal Antigenemia. Journal of Clinical Microbiology, 2020, 58, .	3.9	25
75	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). Open Forum Infectious Diseases, 2020, 7, ofaa130.	0.9	160
76	Methods for rapid diagnosis of meningitis etiology in adults. Biomarkers in Medicine, 2020, 14, 459-479.	1.4	38
77	Host Directed Therapies for Tuberculous Meningitis. Wellcome Open Research, 2020, 5, 292.	1.8	9
78	Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis. Open Forum Infectious Diseases, 2020, 7, ofaa530.	0.9	3
79	Etiology of Sepsis in Uganda Using a Quantitative Polymerase Chain Reaction-based TaqMan Array Card. Clinical Infectious Diseases, 2019, 68, 266-272.	5.8	46
80	Minimum Inhibitory Concentration Distribution of Fluconazole Against Cryptococcus Species and the Fluconazole Exposure Prediction Model. Open Forum Infectious Diseases, 2019, 6, .	0.9	17
81	Identification of Pathogen Genomic Differences That Impact Human Immune Response and Disease during Cryptococcus neoformans Infection. MBio, 2019, 10, .	4.1	39
82	Longitudinal Changes in Cd4+, Cd8+ T Cell Phenotype and Activation Marker Expression Following Antiretroviral Therapy Initiation among Patients with Cryptococcal Meningitis. Journal of Fungi (Basel, Switzerland), 2019, 5, 63.	3.5	3
83	Diagnosis and Management of Central Nervous System Cryptococcal Infections in HIV-Infected Adults. Journal of Fungi (Basel, Switzerland), 2019, 5, 65.	3.5	21
84	Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infectious Diseases, The, 2019, 19, 843-851.	9.1	92
85	Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study. BMC Infectious Diseases, 2019, 19, 558.	2.9	7
86	Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 565-576.	1.8	3
87	Shortâ€course amphotericin B in addition to sertraline and fluconazole for treatment of HIVâ€associated cryptococcal meningitis in rural Tanzania. Mycoses, 2019, 62, 1127-1132.	4.0	13
88	The Changing Epidemiology of HIV-Associated Adult Meningitis, Uganda 2015–2017. Open Forum Infectious Diseases, 2019, 6, ofz419.	0.9	38
89	Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda. Journal of NeuroVirology, 2019, 25, 800-813.	2.1	14
90	New US Food and Drug Administration Approvals Decrease Generic Flucytosine Costs. Clinical Infectious Diseases, 2019, 69, 732-732.	5.8	4

#	Article	IF	CITATIONS
91	Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis. Clinical and Translational Science, 2019, 12, 445-449.	3.1	7
92	Essential in vitro diagnostics for advanced HIV and serious fungal diseases: international experts' consensus recommendations. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1581-1584.	2.9	28
93	HIV-Associated Cryptococcal Immune Reconstitution Inflammatory Syndrome Is Associated with Aberrant T Cell Function and Increased Cytokine Responses. Journal of Fungi (Basel, Switzerland), 2019, 5, 42.	3.5	13
94	The conundrum of clinical trials and standard of care in sub-Saharan Africa – the research nurse perspective. Journal of Research in Nursing, 2019, 24, 649-660.	0.9	10
95	Tuberculosis at the animal–human interface in the Ugandan cattle corridor using a third-generation sequencing platform: a cross-sectional analysis study. BMJ Open, 2019, 9, e024221.	1.9	3
96	Xpert MTB/RIF Ultra for Tuberculosis Testing in Children: A Mini-Review and Commentary. Frontiers in Pediatrics, 2019, 7, 34.	1.9	31
97	The Mouse Inhalation Model of <i>Cryptococcus neoformans</i> Infection Recapitulates Strain Virulence in Humans and Shows that Closely Related Strains Can Possess Differential Virulence. Infection and Immunity, 2019, 87, .	2.2	43
98	Improved detection of group A <i>Streptococcus</i> during thermal contrast amplification <i>vs.</i> visual reading of clinical rapid diagnostic tests. Analytical Methods, 2019, 11, 2013-2017.	2.7	5
99	AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study. BMJ Open, 2019, 9, e026288.	1.9	6
100	Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 &It100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 182-189.	2.1	35
101	Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 205-213.	2.1	19
102	Cryptococcal meningitis is a cause for crossâ€reactivity in cerebrospinal fluid assays for antiâ€ <i>Histoplasma,</i> anti <i>â€Coccidioides</i> and antiâ€ <i>Blastomyces</i> antibodies. Mycoses, 2019, 62, 268-273.	4.0	6
103	Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis. PLoS ONE, 2019, 14, e0210105.	2.5	37
104	Epidemiology of non-traumatic spinal cord injury in Uganda: a single center, prospective study with MRI evaluation. BMC Neurology, 2019, 19, 10.	1.8	14
105	HIV-Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts. Journal of Infectious Diseases, 2019, 219, 877-883.	4.0	43
106	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. Lancet Infectious Diseases, The, 2019, 19, e143-e147.	9.1	63
107	Detection of Cryptococcus DNA by Metagenomic Next-generation Sequencing in Symptomatic Cryptococcal Antigenemia. Clinical Infectious Diseases, 2019, 68, 1978-1979.	5.8	15
108	Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing. Journal of Clinical Microbiology, 2019, 57, .	3.9	115

#	Article	IF	Citations
109	Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis. Clinical Infectious Diseases, 2019, 68, 2094-2098.	5.8	33
110	Seizures in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: Predictors and Outcomes. Open Forum Infectious Diseases, 2019, 6, ofz478.	0.9	15
111	Inadequate diagnostics: the case to move beyond the bacilli for detection of meningitis due to Mycobacterium tuberculosis. Journal of Medical Microbiology, 2019, 68, 755-760.	1.8	31
112	Performance of Lipoarabinomannan Assay using Cerebrospinal fluid for the diagnosis of Tuberculous meningitis among HIV patients. Wellcome Open Research, 2019, 4, 123.	1.8	8
113	Performance of Lipoarabinomannan Assay using Cerebrospinal fluid for the diagnosis of Tuberculous meningitis among HIV patients. Wellcome Open Research, 2019, 4, 123.	1.8	12
114	Standardized approaches for clinical sampling and endpoint ascertainment in tuberculous meningitis studies. Wellcome Open Research, 2019, 4, 204.	1.8	5
115	High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study). Wellcome Open Research, 2019, 4, 190.	1.8	11
116	High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study). Wellcome Open Research, 2019, 4, 190.	1.8	6
117	Standardized approaches for clinical sampling and endpoint ascertainment in tuberculous meningitis studies. Wellcome Open Research, 2019, 4, 204.	1.8	6
118	Xpert Ultra's place in the diagnosis of tuberculous meningitis – Authors' reply. Lancet Infectious Diseases, The, 2018, 18, 249-250.	9.1	1
119	A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 231-238.	2.1	28
120	Absence of cerebrospinal fluid pleocytosis in tuberculous meningitis is a common occurrence in HIV co-infection and a predictor of poor outcomes. International Journal of Infectious Diseases, 2018, 68, 77-78.	3.3	13
121	Cryptococcal Disease in the Era of "Test and Treat― Is There Cause for Concern?. Open Forum Infectious Diseases, 2018, 5, ofx274.	0.9	9
122	Evaluation of trypan blue stain in the TC20 automated cell counter as a point-of-care for the enumeration of viable cryptococcal cells in cerebrospinal fluid. Medical Mycology, 2018, 56, 559-564.	0.7	5
123	Poor specificity of urinary cryptococcal antigen testing. HIV Medicine, 2018, 19, e47-e48.	2.2	3
124	Seroprevalence of Histoplasmosis in Somali, Burmese, and Hmong Refugees Residing in Thailand and Kenya. Journal of Immigrant and Minority Health, 2018, 20, 334-338.	1.6	6
125	Systematic Review of Interventions for Depression for People Living with HIV in Africa. AIDS and Behavior, 2018, 22, 1-8.	2.7	31
126	Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infectious Diseases, The, 2018, 18, 68-75.	9.1	240

#	Article	IF	CITATIONS
127	Are fluconazole or sertraline dose adjustments necessary with concomitant rifampin?. HIV Medicine, 2018, 19, e64-e65.	2,2	2
128	Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection. Wellcome Open Research, 2018, 3, 111.	1.8	0
129	High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study). Wellcome Open Research, 2018, 3, 83.	1.8	16
130	A qualitative evaluation of an implementation study for cryptococcal antigen screening and treatment in Uganda. Medicine (United States), 2018, 97, e11722.	1.0	10
131	AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. Trials, 2018, 19, 649.	1.6	41
132	Blood neutrophil counts in HIV-infected patients with cryptococcal meningitis: Association with mortality. PLoS ONE, 2018, 13, e0209337.	2.5	18
133	Performance of cryptococcal antigen lateral flow assay in serum, cerebrospinal fluid, whole blood, and urine in HIV-infected patients with culture-proven cryptococcal meningitis admitted at a Brazilian referral center. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2018, 60, e1.	1.1	15
134	Cryptococcal Meningitis and Tuberculous Meningitis Co-infection in HIV-Infected Ugandan Adults. Open Forum Infectious Diseases, 2018, 5, ofy193.	0.9	23
135	Cerebral Oximetry for Detecting High-mortality Risk Patients with Cryptococcal Meningitis. Open Forum Infectious Diseases, 2018, 5, ofy105.	0.9	11
136	Xpert MTB/RIF® assay for the diagnosis of HIV-related tuberculous meningitis in São Paulo, Brazil. International Journal of Tuberculosis and Lung Disease, 2018, 22, 706-707.	1.2	7
137	Antimicrobial Drug Resistance in Blood Culture Isolates at a Tertiary Hospital, Uganda. Emerging Infectious Diseases, 2018, 24, 174-175.	4.3	35
138	Detection of Mycobacterium tuberculosis in urine by Xpert MTB/RIF Ultra: A useful adjunctive diagnostic tool in HIV-associated tuberculosis. International Journal of Infectious Diseases, 2018, 75, 92-94.	3.3	23
139	Delta-like 1 protein, vitamin D binding protein and fetuin for detection of Mycobacterium tuberculosismeningitis. Biomarkers in Medicine, 2018, 12, 707-716.	1.4	21
140	Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation. Open Forum Infectious Diseases, 2018, 5, ofy122.	0.9	44
141	Tuberculous meningitis diagnosis and outcomes during the Xpert MTB/Rif era: a 6.5-year cohort study in Uganda. Wellcome Open Research, 2018, 3, 64.	1.8	20
142	Ophthalmic signs in Ugandan adults with HIV-associated cryptococcal meningitis: A nested analysis of the ASTRO-CM cohort. Wellcome Open Research, 2018, 3, 80.	1.8	4
143	Evaluation of a point-of-care immunoassay test kit  StrongStep' for cryptococcal antigen detection. PLoS ONE, 2018, 13, e0190652.	2.5	22
144	Cryptococcosis and HIV. , 2018, , 397-409.		0

#	Article	IF	CITATIONS
145	Ophthalmic signs in Ugandan adults with HIV-associated cryptococcal meningitis: A nested analysis of the ASTRO-CM cohort. Wellcome Open Research, 2018, 3, 80.	1.8	3
146	Case Report: Three's a crowd: a case report examining the diagnostic and pharmacokinetic challenges in HIV-tuberculous meningitis-malaria co-infection. Wellcome Open Research, 2018, 3, 111.	1.8	0
147	Activity of VT-1129 against <i>Cryptococcus neoformans</i> clinical isolates with high fluconazole MICs. Medical Mycology, 2017, 55, myw089.	0.7	22
148	Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis. HIV Medicine, 2017, 18, 13-20.	2.2	24
149	Recent advances in AIDS-related cryptococcal meningitis treatment with an emphasis on resource limited settings. Expert Review of Anti-Infective Therapy, 2017, 15, 331-340.	4.4	13
150	Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis. Journal of Infectious Diseases, 2017, 215, 693-697.	4.0	20
151	Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infectious Diseases, The, 2017, 17, 873-881.	9.1	1,559
152	Recent Increases in the U.S. Maternal Mortality Rate: Disentangling Trends From Measurement Issues. Obstetrics and Gynecology, 2017, 129, 385-386.	2.4	0
153	The CSF Immune Response in HIV-1–Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 299-307.	2.1	23
154	Case 8-2017. New England Journal of Medicine, 2017, 376, 1065-1071.	27.0	2
154 155	Case 8-2017. New England Journal of Medicine, 2017, 376, 1065-1071. Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda. Journal of NeuroVirology, 2017, 23, 369-375.	27.0	2 46
	Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected		
155	Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda. Journal of NeuroVirology, 2017, 23, 369-375. Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)–Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening	2.1	46
155 156	Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda. Journal of NeuroVirology, 2017, 23, 369-375. Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)–Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program. Clinical Infectious Diseases, 2017, 65, 2126-2129. Acute Kidney Injury and Urinary Biomarkers in Human Immunodeficiency Virus–Associated	2.1 5.8	46 54
155 156 157	Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda. Journal of NeuroVirology, 2017, 23, 369-375. Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)–Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program. Clinical Infectious Diseases, 2017, 65, 2126-2129. Acute Kidney Injury and Urinary Biomarkers in Human Immunodeficiency Virus–Associated Cryptococcal Meningitis. Open Forum Infectious Diseases, 2017, 4, ofx127. The Role of Nanoparticle Design in Determining Analytical Performance of Lateral Flow	2.1 5.8 0.9	46 54 4
155 156 157	Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda. Journal of NeuroVirology, 2017, 23, 369-375. Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)–Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program. Clinical Infectious Diseases, 2017, 65, 2126-2129. Acute Kidney Injury and Urinary Biomarkers in Human Immunodeficiency Virus–Associated Cryptococcal Meningitis. Open Forum Infectious Diseases, 2017, 4, ofx127. The Role of Nanoparticle Design in Determining Analytical Performance of Lateral Flow Immunoassays. Nano Letters, 2017, 17, 7207-7212.	2.1 5.8 0.9 9.1	46 54 4 149
155 156 157 158	Cerebrospinal fluid biomarkers and HIV-associated neurocognitive disorders in HIV-infected individuals in Rakai, Uganda. Journal of NeuroVirology, 2017, 23, 369-375. Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)–Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program. Clinical Infectious Diseases, 2017, 65, 2126-2129. Acute Kidney Injury and Urinary Biomarkers in Human Immunodeficiency Virus–Associated Cryptococcal Meningitis. Open Forum Infectious Diseases, 2017, 4, ofx127. The Role of Nanoparticle Design in Determining Analytical Performance of Lateral Flow Immunoassays. Nano Letters, 2017, 17, 7207-7212. Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts. BMC Neurology, 2017, 17, 110. Is it possible to differentiate tuberculous and cryptococcal meningitis in HIV-infected patients using only clinical and basic cerebrospinal fluid characteristics?. South African Medical Journal, 2017, 107,	2.1 5.8 0.9 9.1	46 54 4 149

#	Article	IF	Citations
163	Performance of nested RT-PCR on CSF for tuberculous meningitis diagnosis in HIV-infected patients. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1139-1144.	1.2	5
164	Evaluation of trypan blue stain in a haemocytometer for rapid detection of cerebrospinal fluid sterility in HIV patients with cryptococcal meningitis. BMC Microbiology, 2017, 17, 182.	3.3	8
165	Monocyte Phenotype and IFN- \hat{l}^3 -Inducible Cytokine Responses Are Associated with Cryptococcal Immune Reconstitution Inflammatory Syndrome. Journal of Fungi (Basel, Switzerland), 2017, 3, 28.	3.5	15
166	Cryptococcal meningitis: A neglected NTD?. PLoS Neglected Tropical Diseases, 2017, 11, e0005575.	3.0	47
167	Hookworm infection is associated with decreased CD4+ T cell counts in HIV-infected adult Ugandans. PLoS Neglected Tropical Diseases, 2017, 11, e0005634.	3.0	21
168	Acridine orange fluorescent microscopy is more sensitive than India ink light microscopy in the rapid detection of cryptococcosis among CrAg positive HIV patients. PLoS ONE, 2017, 12, e0182108.	2.5	12
169	Socioeconomic position and ten-year survival and virologic outcomes in a Ugandan HIV cohort receiving antiretroviral therapy. PLoS ONE, 2017, 12, e0189055.	2.5	19
170	CD4+ T-cell Count may not be a Useful Strategy to Monitor Antiretroviral Therapy Response in HTLV-1/HIV Co-infected Patients. Current HIV Research, 2017, 15, 225-231.	0.5	17
171	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 65-69.	2.1	2
172	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e32-e36.	2.1	9
173	The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome. Current Opinion in Infectious Diseases, 2016, 29, 10-22.	3.1	40
174	Fatty Liver in Hispanics with HIV. AIDS Research and Human Retroviruses, 2016, 32, 515-516.	1.1	2
175	Fighting the Monster: Applying the Host Damage Framework to Human Central Nervous System Infections. MBio, 2016, 7, e01906-15.	4.1	32
176	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 462-466.	2.1	8
177	Sertraline for HIV-associated cryptococcal meningitis – Authors' reply. Lancet Infectious Diseases, The, 2016, 16, 1111-1112.	9.1	2
178	Asymptomatic cryptococcal antigen prevalence detected by lateral flow assay in hospitalised HIV-infected patients in São Paulo, Brazil. Tropical Medicine and International Health, 2016, 21, 1539-1544.	2.3	32
179	Thermal Contrast Amplification Reader Yielding 8-Fold Analytical Improvement for Disease Detection with Lateral Flow Assays. Analytical Chemistry, 2016, 88, 11774-11782.	6.5	81
180	Diagnostic Delay and Antibiotic Overuse in Acute Pulmonary Blastomycosis. Open Forum Infectious Diseases, 2016, 3, ofw078.	0.9	23

#	Article	IF	CITATIONS
181	A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis. Journal of Infectious Diseases, 2016, 213, 1725-1734.	4.0	37
182	Human Immune Response Varies by the Degree of Relative Cryptococcal Antigen Shedding. Open Forum Infectious Diseases, 2016, 3, ofv194.	0.9	18
183	Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis. Clinical Infectious Diseases, 2016, 62, 1564-1568.	5 . 8	43
184	Seroprevalence of histoplasmosis in Kampala, Uganda. Medical Mycology, 2016, 54, 295-300.	0.7	21
185	Personal Protection Measures Against Mosquitoes, Ticks, and Other Arthropods. Medical Clinics of North America, 2016, 100, 303-316.	2.5	33
186	Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis. Medical Mycology, 2016, 54, 361-369.	0.7	38
187	Flow Cytometry To Assess Cerebrospinal Fluid Fungal Burden in Cryptococcal Meningitis. Journal of Clinical Microbiology, 2016, 54, 802-804.	3.9	7
188	Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infectious Diseases, The, 2016, 16, 809-818.	9.1	161
189	Diagnostic performance of a multiplex PCR assay for meningitis in an HIV-infected population in Uganda. Diagnostic Microbiology and Infectious Disease, 2016, 84, 268-273.	1.8	92
190	A Word of Caution in Considering the Use of the Lipoarabinomannan Lateral Flow Assay on Cerebrospinal Fluid for Detection of Tuberculous Meningitis. Journal of Clinical Microbiology, 2016, 54, 241-242.	3.9	11
191	Leptospira Seroprevalence and Risk Factors in Health Centre Patients in Hoima District, Western Uganda. PLoS Neglected Tropical Diseases, 2016, 10, e0004858.	3.0	28
192	Cryptococcosis and HIV., 2016, , 1-12.		0
193	Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis. Open Forum Infectious Diseases, 2015, 2, ofv157.	0.9	22
194	LATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITY. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2015, 57, 38-45.	1.1	84
195	Towards a scalable HIV cure research agenda: the role of co-infections. Journal of Virus Eradication, 2015, 1, 269-271.	0.5	3
196	Epidemiology of Meningitis in an HIV-Infected Ugandan Cohort. American Journal of Tropical Medicine and Hygiene, 2015, 92, 274-279.	1.4	60
197	Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. Open Forum Infectious Diseases, 2015, 2, ofv046.	0.9	68
198	1,3-β-D-glucan in cryptococcal meningitis. Lancet Infectious Diseases, The, 2015, 15, 1136-1137.	9.1	11

#	Article	IF	Citations
199	Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution. International Journal of STD and AIDS, 2015, 26, 912-914.	1.1	19
200	HIV care: ART adherence support and cryptococcal screening. Lancet, The, 2015, 385, 2128-2129.	13.7	6
201	Gastrointestinal cryptococcoma – Immune reconstitution inflammatory syndrome or cryptococcal relapse in a patient with AIDS?. Medical Mycology Case Reports, 2015, 8, 40-43.	1.3	7
202	Low rates of Hepatitis B and Human Immunodeficiency Virus coinfection in rural northern Tanzania. Journal of Global Infectious Diseases, 2015, 7, 47.	0.5	2
203	Chitin Recognition via Chitotriosidase Promotes Pathologic Type-2 Helper T Cell Responses to Cryptococcal Infection. PLoS Pathogens, 2015, 11, e1004701.	4.7	162
204	Cryptococcal Meningitis: Diagnosis and Management Update. Current Tropical Medicine Reports, 2015, 2, 90-99.	3.7	123
205	Early ART After Cryptococcal Meningitis Is Associated With Cerebrospinal Fluid Pleocytosis and Macrophage Activation in a Multisite Randomized Trial. Journal of Infectious Diseases, 2015, 212, 769-778.	4.0	60
206	Illuminating meningococcal diagnosis with LAMP. Lancet Infectious Diseases, The, 2015, 15, 494-495.	9.1	0
207	Cellular Immune Activation in Cerebrospinal Fluid From Ugandans With Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome. Journal of Infectious Diseases, 2015, 211, 1597-1606.	4.0	55
208	Evaluation of Fingerstick Cryptococcal Antigen Lateral Flow Assay in HIV-Infected Persons: A Diagnostic Accuracy Study: Figure 1 Clinical Infectious Diseases, 2015, 61, 464-467.	5.8	81
209	Lumbar puncture refusal in sub-Saharan Africa: A call for further understanding and intervention. Neurology, 2015, 84, 1988-1990.	1.1	64
210	Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda. Antimicrobial Agents and Chemotherapy, 2015, 59, 7197-7204.	3.2	151
211	Improved diagnostic sensitivity for tuberculous meningitis with Xpert [®] MTB/RIF of centrifuged CSF. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1209-1215.	1.2	104
212	Towards a scalable HIV cure research agenda: the role of co-infections. Journal of Virus Eradication, 2015, 1, 269-271.	0.5	1
213	Performance of Cryptococcal Antigen Lateral Flow Assay Using Saliva in Ugandans with CD4 <100. PLoS ONE, 2014, 9, e103156.	2.5	22
214	Unmasking Cryptococcal Meningitis Immune Reconstitution Inflammatory Syndrome due to Granulocyte Colony-Stimulating Factor Use in a Patient with a Poorly Differentiated Germ Cell Neoplasm. Case Reports in Oncology, 2014, 7, 1-5.	0.7	8
215	Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-Limited Settings. Open Forum Infectious Diseases, 2014, 1, ofu070.	0.9	36
216	Methods of rapid diagnosis for the etiology of meningitis in adults. Biomarkers in Medicine, 2014, 8, 1085-1103.	1.4	81

#	Article	IF	CITATIONS
217	Detection of High Cerebrospinal Fluid Levels of $(1\hat{a}^{\dagger})^2$ -d-Glucan in Cryptococcal Meningitis. Open Forum Infectious Diseases, 2014, 1, ofu105.	0.9	35
218	Multisite Validation of Cryptococcal Antigen Lateral Flow Assay and Quantification by Laser Thermal Contrast. Emerging Infectious Diseases, 2014, 20, 45-53.	4.3	253
219	Nosocomial Drug-Resistant Bacteremia in 2 Cohorts with Cryptococcal Meningitis, Africa. Emerging Infectious Diseases, 2014, 20, 722-724.	4.3	14
220	The Cryptococcus neoformans Transcriptome at the Site of Human Meningitis. MBio, 2014, 5, e01087-13.	4.1	113
221	The Effect of Therapeutic Lumbar Punctures on Acute Mortality From Cryptococcal Meningitis. Clinical Infectious Diseases, 2014, 59, 1607-1614.	5.8	145
222	Antiretroviral Therapy after Cryptococcal Meningitis. New England Journal of Medicine, 2014, 371, 1165-1167.	27.0	4
223	Cryptococcus neoformans Ex Vivo Capsule Size Is Associated With Intracranial Pressure and Host Immune Response in HIV-associated Cryptococcal Meningitis. Journal of Infectious Diseases, 2014, 209, 74-82.	4.0	90
224	Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study. Metabolic Brain Disease, 2014, 29, 269-279.	2.9	45
225	Point-of-Care Diagnosis and Prognostication of Cryptococcal Meningitis With the Cryptococcal Antigen Lateral Flow Assay on Cerebrospinal Fluid. Clinical Infectious Diseases, 2014, 58, 113-116.	5.8	107
226	Accuracy of Noninvasive Intraocular Pressure or Optic Nerve Sheath Diameter Measurements for Predicting Elevated Intracranial Pressure in Cryptococcal Meningitis. Open Forum Infectious Diseases, 2014, 1, ofu093.	0.9	34
227	Central nervous system cryptococcoma in a Ugandan patient with Human Immunodeficiency Virus. Medical Mycology Case Reports, 2014, 6, 10-13.	1.3	11
228	Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis. New England Journal of Medicine, 2014, 370, 2487-2498.	27.0	387
229	Unmasking cryptococcal meningitis immune reconstitution inflammatory syndrome in pregnancy induced by HIV antiretroviral therapy with postpartum paradoxical exacerbation. Medical Mycology Case Reports, 2014, 5, 16-19.	1.3	14
230	Central Nervous System Immune Reconstitution Inflammatory Syndrome. Current Infectious Disease Reports, 2013, 15, 583-593.	3.0	83
231	Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America. Brazilian Journal of Infectious Diseases, 2013, 17, 353-362.	0.6	47
232	Accuracy of Pima Point-of-Care CD4 Analyzer in Routine Use in Public Health Clinics in Uganda. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, e113-e115.	2.1	6
233	Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses. Journal of Infectious Diseases, 2013, 207, 1379-1388.	4.0	39
234	Utility of the Xpert MTB/RIF Assay for Diagnosis of Tuberculous Meningitis. PLoS Medicine, 2013, 10, e1001537.	8.4	13

#	Article	IF	CITATIONS
235	P5.074â€Immune Activation After Stimulation with Cryptococcus Neoformans Antigens Pre and Post ART Initiation in HIV-1 Positive Ugandans. Sexually Transmitted Infections, 2013, 89, A357.3-A358.	1.9	O
236	Cost-Effective Diagnostic Checklists for Meningitis in Resource-Limited Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, e101-e108.	2.1	91
237	Comparison of Cryptococcal Antigenemia between Antiretroviral Na \tilde{A} ve and Antiretroviral Experienced HIV Positive Patients at Two Hospitals in Ethiopia. PLoS ONE, 2013, 8, e75585.	2.5	44
238	Diagnosis and Management of Cryptococcal Relapse. Journal of AIDS & Clinical Research, 2013, 01, .	0.5	42
239	Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update. Southern African Journal of HIV Medicine, 2013, 14, 76.	0.9	19
240	Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis. PLoS Medicine, 2012, 9, e1001316.	8.4	79
241	Cryptococcal Genotype Influences Immunologic Response and Human Clinical Outcome after Meningitis. MBio, 2012, 3, .	4.1	79
242	Role of quantitative CSF microscopy to predict culture status and outcome in HIV-associated cryptococcal meningitis in a Brazilian cohort. Diagnostic Microbiology and Infectious Disease, 2012, 73, 68-73.	1.8	28
243	Reconsidering Cryptococcal Antigen Screening in the U.S. Among Persons With CD4 < 100 cells/mcL. Clinical Infectious Diseases, 2012, 55, 1742-1744.	5.8	30
244	Long Term 5-Year Survival of Persons with Cryptococcal Meningitis or Asymptomatic Subclinical Antigenemia in Uganda. PLoS ONE, 2012, 7, e51291.	2.5	55
245	Integrating Cryptococcal Antigen Screening and Pre-Emptive Treatment into Routine HIV Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, e85-e91.	2.1	143
246	Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings. African Health Sciences, 2012, 12, 226-30.	0.7	26
247	Acute Heart Failure From Lyme Carditis. Circulation: Heart Failure, 2012, 5, e24-6.	3.9	27
248	Significantly Improved Analytical Sensitivity of Lateral Flow Immunoassays by Using Thermal Contrast. Angewandte Chemie - International Edition, 2012, 51, 4358-4361.	13.8	155
249	Cryptococcus: from human pathogen to model yeast. Lancet Infectious Diseases, The, 2011, 11, 434.	9.1	5
250	Tuberculosis in human immunodeficiency virus infected Ugandan children starting on antiretroviral therapy. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1082-1086.	1.2	31
251	Cryptococcus-Related Immune Reconstitution Inflammatory Syndrome (IRIS): Pathogenesis and its Clinical Implications. Current Fungal Infection Reports, 2011, 5, 252-261.	2.6	61
252	Comparative Genome Sequencing of an Isogenic Pair of USA800 Clinical Methicillin-Resistant Staphylococcus aureus Isolates Obtained before and after Daptomycin Treatment Failure. Antimicrobial Agents and Chemotherapy, 2011, 55, 2018-2025.	3.2	59

#	Article	IF	Citations
253	Higher Levels of CRP, D-dimer, IL-6, and Hyaluronic Acid Before Initiation of Antiretroviral Therapy (ART) Are Associated With Increased Risk of AIDS or Death. Journal of Infectious Diseases, 2011, 203, 1637-1646.	4.0	287
254	Impact of Global Health Residency Training on Medical Knowledge of Immigrant Health. American Journal of Tropical Medicine and Hygiene, 2011, 85, 405-408.	1.4	26
255	The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children. Aids, 2010, 24, 2009-2017.	2.2	43
256	Physician Preferences for Elements of Effective Consultations. Journal of General Internal Medicine, 2010, 25, 25-30.	2.6	27
257	Paucity of Initial Cerebrospinal Fluid Inflammation in Cryptococcal Meningitis Is Associated with Subsequent Immune Reconstitution Inflammatory Syndrome. Journal of Infectious Diseases, 2010, 202, 962-970.	4.0	180
258	Costâ€Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIVâ€Infected Persons with a CD4 ⁺ Cell Count ⩽100 Cells/ξL Who Start HIV Therapy in Resourceâ€Limited Settings. Clinical Infectious Diseases, 2010, 51, 448-455.	5.8	280
259	Safety, Censoring, and Intentâ€ŧoâ€₹reat Analysis: Dangers to Generalizability. Clinical Infectious Diseases, 2010, 51, 985-986.	5.8	4
260	Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study. PLoS Medicine, 2010, 7, e1000384.	8.4	245
261	Reduction of Immune Activation with Chloroquine Therapy during Chronic HIV Infection. Journal of Virology, 2010, 84, 12082-12086.	3.4	121
262	Antiretroviral Therapy Down-Regulates Innate Antiviral Response Genes in Patients With AIDS in Sub-Saharan Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 428-438.	2.1	23
263	Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infectious Diseases, The, 2010, 10, 791-802.	9.1	271
264	Diagnostic Performance of Rapid Diagnostic Tests versus Blood Smears for Malaria in US Clinical Practice. Clinical Infectious Diseases, 2009, 49, 908-913.	5.8	92
265	Migrants, detainees, and misconceptions. Lancet, The, 2009, 373, 2112.	13.7	0
266	Biomarkers of HIV immune reconstitution inflammatory syndrome. Biomarkers in Medicine, 2008, 2, 349-361.	1.4	64
267	Tuberculosis Immune Reconstitution Syndrome Among Ugandan Children. International Journal of Infectious Diseases, 2008, 12, e63-e64.	3.3	3
268	Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 46, 1694-1701.	5.8	278
269	Pediatric HIV immune reconstitution inflammatory syndrome. Current Opinion in HIV and AIDS, 2008, 3, 461-467.	3.8	50
270	HIV Immune Reconstitution Inflammatory Syndrome. , 2008, , 193-205.		1

#	Article	IF	Citations
271	Hypereosinophilic syndrome and mepolizumab. New England Journal of Medicine, 2008, 358, 2839; author reply 2839-40.	27.0	3
272	The trials of the returning traveler: ciprofloxacin failure in enteric fever. Minnesota Medicine, 2008, 91, 43-4.	0.1	0
273	Maltreatment of Strongyloides Infection: Case Series and Worldwide Physicians-in-Training Survey. American Journal of Medicine, 2007, 120, 545.e1-545.e8.	1.5	106
274	Injuries in Bouldering: A Prospective Study. Wilderness and Environmental Medicine, 2007, 18, 271-280.	0.9	69
275	Diseases with Long Latency Periods. , 2007, , 233-243.		0
276	Strongyloides. , 2007, , 509-513.		1
277	Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection. Journal of Infection, 2007, 55, 300-309.	3.3	73
278	Financial Implications of Refugee Malaria: The Impact of Pre-Departure Presumptive Treatment with Anti-Malarial Drugs. American Journal of Tropical Medicine and Hygiene, 2007, 77, 458-463.	1.4	17
279	Financial implications of refugee malaria: the impact of pre-departure presumptive treatment with anti-malarial drugs. American Journal of Tropical Medicine and Hygiene, 2007, 77, 458-63.	1.4	6
280	Travel Medicine for the Extreme Traveler. Disease-a-Month, 2006, 52, 309-325.	1.1	3
281	A case for treating high hepatitis B DNA levels before starting HIV therapy. Aids, 2006, 20, 2402-2403.	2.2	7
282	A Randomized, Controlled Field Trial for the Prevention of Jellyfish Stings With a Topical Sting Inhibitor. Journal of Travel Medicine, 2006, 13, 166-171.	3.0	51
283	Passive Prophylaxis With Permethrin-Treated Tents Reduces Mosquito Bites Among North American Summer Campers. Wilderness and Environmental Medicine, 2005, 16, 9-15.	0.9	15
284	Strongyloides Hyperinfection Presenting as Acute Respiratory Failure and Gram-Negative Sepsis. Chest, 2005, 128, 3681-3684.	0.8	117
285	Travel Medicine Considerations for North American Immigrants Visiting Friends and Relatives. JAMA - Journal of the American Medical Association, 2004, 291, 2856.	7.4	213
286	Gender Differences Among Long-Distance Backpackers: A Prospective Study of Women Appalachian Trail Backpackers. Wilderness and Environmental Medicine, 2004, 15, 175-180.	0.9	21
287	Influence of Hygiene on Gastrointestinal Illness among Wilderness Backpackers. Journal of Travel Medicine, 2004, 11, 27-33.	3.0	28
288	Backpacking-Induced Paresthesias. Wilderness and Environmental Medicine, 2003, 14, 161-166.	0.9	32

#	Article	IF	CITATIONS
289	Medical risks of wilderness hiking. American Journal of Medicine, 2003, 114, 288-293.	1.5	72
290	The effect of sertraline on depression and associations with persistent depression in survivors of HIV-related cryptococcal meningitis. Wellcome Open Research, 0, 6, 45.	1.8	3
291	Host Directed Therapies for Tuberculous Meningitis. Wellcome Open Research, 0, 5, 292.	1.8	6
292	Neurocognitive outcomes of HIV-associated tuberculous meningitis. Wellcome Open Research, 0, 6, 208.	1.8	2
293	Can improved diagnostics reduce mortality from Tuberculous meningitis? Findings from a 6.5-year cohort in Uganda. Wellcome Open Research, 0, 3, 64.	1.8	5
294	Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials. Open Forum Infectious Diseases, 0, , .	0.9	0
295	Pneumococcal Pneumonia in Adults: Epidemiology, Clinical Features, Diagnosis, and Therapy. , 0, , 117-138.		1
296	Rates of refusal of clinical autopsies among HIV-positive decedents and an overview of autopsies in Uganda. Wellcome Open Research, 0, 6, 302.	1.8	1
297	Neurocognitive outcomes of tuberculous meningitis in a primarily HIV-positive Ugandan cohort. Wellcome Open Research, 0, 6, 208.	1.8	0
298	Diagnostic and Prognostic Value of Cerebrospinal Fluid Lactate and Glucose in HIV-Associated Tuberculosis Meningitis. Microbiology Spectrum, 0, , .	3.0	3